Novartis eyes its next move in gene therapy
Bio Pharma Dive
OCTOBER 29, 2020
Acquiring Vedere Bio, an Atlas Venture-backed startup, gives Novartis a technology it believes will be valuable for developing treatments for many causes of vision loss and blindness.
Let's personalize your content